Medica Venture Partners

Regentis Biomaterials Ltd. is a company specializing in tissue repair, particularly in the development and commercialization of biodegradable hydrogels for repairing damaged cartilage tissue. Founded in 2004 and based in Or-Akiva, Israel, with an additional office in Princeton, New Jersey, the company’s core technology includes Gelrin, a hydrogel matrix composed of polyethylene glycol diacrylate and denatured fibrinogen. This innovative platform merges the stability of synthetic materials with the bio-functionality of natural substances, catering to various clinical applications. Regentis's flagship product, GelrinC, is designed for treating articular cartilage lesions and is currently undergoing clinical trials. The company’s focus is on orthopedic treatments, aiming to restore health and improve the quality of life for patients suffering from cartilage damage and related conditions.

Regentis Biomaterials Ltd. is a company specializing in tissue repair, particularly in the development and commercialization of biodegradable hydrogels for repairing damaged cartilage tissue. Founded in 2004 and based in Or-Akiva, Israel, with an additional office in Princeton, New Jersey, the company’s core technology includes Gelrin, a hydrogel matrix composed of polyethylene glycol diacrylate and denatured fibrinogen. This innovative platform merges the stability of synthetic materials with the bio-functionality of natural substances, catering to various clinical applications. Regentis's flagship product, GelrinC, is designed for treating articular cartilage lesions and is currently undergoing clinical trials. The company’s focus is on orthopedic treatments, aiming to restore health and improve the quality of life for patients suffering from cartilage damage and related conditions.

SuperDimension is a privately-held medical device company that specializes in developing and marketing minimally-invasive pulmonology devices aimed at diagnosing and treating distal lung disease. The company’s main product, the i·Logic System, includes both capital equipment and disposable tools designed to enhance traditional bronchoscopy techniques. These innovations allow physicians to access peripheral lung lesions and mediastinal lymph nodes, facilitating the diagnosis of previously inaccessible lung conditions at earlier stages when they may be more treatable. SuperDimension is committed to becoming a leader in the field of distal lung disease diagnosis and treatment, addressing a significant market of over 8 million patients.

SuperDimension is a privately-held medical device company that specializes in developing and marketing minimally-invasive pulmonology devices aimed at diagnosing and treating distal lung disease. The company’s main product, the i·Logic System, includes both capital equipment and disposable tools designed to enhance traditional bronchoscopy techniques. These innovations allow physicians to access peripheral lung lesions and mediastinal lymph nodes, facilitating the diagnosis of previously inaccessible lung conditions at earlier stages when they may be more treatable. SuperDimension is committed to becoming a leader in the field of distal lung disease diagnosis and treatment, addressing a significant market of over 8 million patients.

Regentis Biomaterials Ltd. is a company specializing in tissue repair, particularly in the development and commercialization of biodegradable hydrogels for repairing damaged cartilage tissue. Founded in 2004 and based in Or-Akiva, Israel, with an additional office in Princeton, New Jersey, the company’s core technology includes Gelrin, a hydrogel matrix composed of polyethylene glycol diacrylate and denatured fibrinogen. This innovative platform merges the stability of synthetic materials with the bio-functionality of natural substances, catering to various clinical applications. Regentis's flagship product, GelrinC, is designed for treating articular cartilage lesions and is currently undergoing clinical trials. The company’s focus is on orthopedic treatments, aiming to restore health and improve the quality of life for patients suffering from cartilage damage and related conditions.

FlowMedica is a medical device company specializing in intravascular systems for Targeted Renal Therapy. The company develops innovative solutions aimed at addressing kidney dysfunction associated with cardiovascular disease, cancer, and surgical procedures. Its flagship product, the Benephit CV Infusion System, enables physicians to deliver therapeutic agents directly into the renal arteries through an infusion catheter, facilitating simultaneous coronary procedures via a single access point in the femoral artery. Additionally, the Benephit XTMini Infusion System caters to patients with smaller vascular anatomies by allowing bilateral infusion to the kidneys. FlowMedica's devices present a precise alternative to traditional systemic intravenous infusion methods, enabling surgeons to administer treatments directly and accurately.

SuperDimension is a privately-held medical device company that specializes in developing and marketing minimally-invasive pulmonology devices aimed at diagnosing and treating distal lung disease. The company’s main product, the i·Logic System, includes both capital equipment and disposable tools designed to enhance traditional bronchoscopy techniques. These innovations allow physicians to access peripheral lung lesions and mediastinal lymph nodes, facilitating the diagnosis of previously inaccessible lung conditions at earlier stages when they may be more treatable. SuperDimension is committed to becoming a leader in the field of distal lung disease diagnosis and treatment, addressing a significant market of over 8 million patients.

InterCure Ltd. is a medical device company that specializes in the development of innovative technologies for the treatment of cardiovascular and pulmonary diseases. Founded in 1994 and based in Hadera, Israel, InterCure has created a patented technology platform known as "Interactive Respiratory-Pacing." This platform has led to the development of product lines that offer non-drug treatments for prevalent conditions such as hypertension and heart failure. The company's flagship product, RESPeRATE, is the only FDA-cleared medical device shown to effectively reduce high blood pressure without side effects. Additionally, InterCure's heart failure treatment, InTone™, has successfully completed phase 2a clinical trials and is awaiting regulatory approval for market launch. With a strong management team and an esteemed Scientific Advisory Board, InterCure aims to lead the market in patient-focused medical devices that address significant health challenges without reliance on pharmaceuticals.

Remon Medical Technologies is a development-stage company based in Caesarea, Israel, specializing in communication technology for medical device applications. It focuses on creating innovative miniature implants and medical devices to improve patient monitoring. The company's flagship products include RemonCHF, which is designed to monitor the hemodynamic status of patients suffering from congestive heart failure, and RemonAAA, a device that tracks pressure levels following endograft procedures in patients with abdominal aortic aneurysms. Through its advanced monitoring solutions, Remon Medical Technologies aims to enhance patient care and outcomes in critical healthcare scenarios.

FlowMedica is a medical device company specializing in intravascular systems for Targeted Renal Therapy. The company develops innovative solutions aimed at addressing kidney dysfunction associated with cardiovascular disease, cancer, and surgical procedures. Its flagship product, the Benephit CV Infusion System, enables physicians to deliver therapeutic agents directly into the renal arteries through an infusion catheter, facilitating simultaneous coronary procedures via a single access point in the femoral artery. Additionally, the Benephit XTMini Infusion System caters to patients with smaller vascular anatomies by allowing bilateral infusion to the kidneys. FlowMedica's devices present a precise alternative to traditional systemic intravenous infusion methods, enabling surgeons to administer treatments directly and accurately.

Dynogen is a privately held, neuroscience-based pharmaceutical company focused on genitourinary (GU) and gastrointestinal (GI) disorders. The company is utilizing its knowledge of the nexus between neurology and GU/GI disorders, as well as its predictive in vitro and in vivo pharmacology platforms to rapidly build a pipeline of development programs. Today, Dynogen has two ongoing development programs, one for overactive bladder (OAB) and another for irritable bowel syndrome (IBS). The company will advance its OAB program into Phase IIa trials and enter the clinic with its IBS program later this year.

SuperDimension is a privately-held medical device company that specializes in developing and marketing minimally-invasive pulmonology devices aimed at diagnosing and treating distal lung disease. The company’s main product, the i·Logic System, includes both capital equipment and disposable tools designed to enhance traditional bronchoscopy techniques. These innovations allow physicians to access peripheral lung lesions and mediastinal lymph nodes, facilitating the diagnosis of previously inaccessible lung conditions at earlier stages when they may be more treatable. SuperDimension is committed to becoming a leader in the field of distal lung disease diagnosis and treatment, addressing a significant market of over 8 million patients.

As of January 27, 2004, Percutaneous Valve Technologies was acquired by Edwards Lifesciences Corp. The company develops medical devices for delivering heart valves to treat late-stage aortic stenosis. Percutaneous Valve Technologies, Inc. was founded in 1999 and is based in Fort Lee, New Jersey.

Impella CardioSystems AG, located in Aachen, Germany, specializes in the development, manufacturing, and marketing of minimally invasive cardiovascular support systems designed for various cardiology and coronary surgery applications. The company produces intracorporeal micro blood pumps, which are utilized to support patients undergoing these medical procedures. With a robust portfolio of over 30 European and international patents protecting its innovative technology, Impella employs a team of 50 individuals. For the past two years, the company has collaborated with Accelerated Technologies, Inc., a medical device accelerator based in Hackensack, New Jersey, to enhance its growth and development in the medical device sector.

Orex Computed Radiography manufactures computerized radiography solutions. The company’s products includes Kodak Point-of-Care CR120, CR140, and CR260 that enables medical practitioners to acquire patient digital x-ray images from around the world. KODAK Point-of-Care CR-ITX 560 is a solution system that brings digital x-ray imaging directly to the patient. KODAK CR 7400 Digital Radiography is a system that delivers intraoral and extra oral images digitally. Orex Computed Radiography is an Israel-based company that was founded in 1996. The company was acquired by Kodak on January 19, 2005.

InterCure Ltd. is a medical device company that specializes in the development of innovative technologies for the treatment of cardiovascular and pulmonary diseases. Founded in 1994 and based in Hadera, Israel, InterCure has created a patented technology platform known as "Interactive Respiratory-Pacing." This platform has led to the development of product lines that offer non-drug treatments for prevalent conditions such as hypertension and heart failure. The company's flagship product, RESPeRATE, is the only FDA-cleared medical device shown to effectively reduce high blood pressure without side effects. Additionally, InterCure's heart failure treatment, InTone™, has successfully completed phase 2a clinical trials and is awaiting regulatory approval for market launch. With a strong management team and an esteemed Scientific Advisory Board, InterCure aims to lead the market in patient-focused medical devices that address significant health challenges without reliance on pharmaceuticals.

As of January 27, 2004, Percutaneous Valve Technologies was acquired by Edwards Lifesciences Corp. The company develops medical devices for delivering heart valves to treat late-stage aortic stenosis. Percutaneous Valve Technologies, Inc. was founded in 1999 and is based in Fort Lee, New Jersey.